FLT3 and acute myeloid leukemia: Another Wnt/β-catenin inhibitor, BC2059 has shown promising results in treatment of AML stem or blast progenitor cells with FLT3 internal tandem duplication expression in combination with receptor tyrosine kinase inhibitors quizartinib and crenolanib (144).